Dean Elterman, MD, on the shift toward personalized care in BPH

The treatment landscape in benign prostatic hyperplasia (BPH) is shifting toward more personalized approaches to care, according to Dean Elterman, MD, MSc, of the University of Toronto.

In a recent interview with Urology Times®, Elterman emphasized the growing need to align treatment decisions with patient-defined outcomes—particularly in terms of symptom relief and quality of life. He also highlighted a rising interest in first-line interventional therapies (FITs), a category of minimally invasive treatments designed to offer symptom control while preserving sexual function.

Elterman recently presented new data on one of these options—the Zenflow Spring System—at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada.¹

Elterman noted that the interest in FITs is only going to continue to grow.

“We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of what is important to them with values and preferences, as well as their individual prostate,” Elterman explained. “As we understand a little bit more about prostate anatomy, shape, and size, and also understand that patients want to have an improvement in their symptoms, [and] also preservation of sexual function in a lot of men, the idea of being able to introduce these minimally invasive treatments, or first-line interventional therapies, FITs, like the Zenflow Spring System, is really important. These types of technologies are going to become more and more popular and needed, especially as we have this aging population.”

REFERENCE

1. Elterman D, Gilling P, Chin P, et al. 36-month outcomes from the ZEST pilot studies of the Zenflow Spring System for the treatment of benign prostatic hyperplasia (BPH). J Urol. 2025;213(5S):e277. doi:10.1097/01.JU.0001109800.53897.68.12